Cargando…

The making of a potent L-lactate transport inhibitor

L-lactate is an important metabolite, energy source, and signaling molecule in health and disease. In mammals, its transport across biological membranes is mediated by monocarboxylate transporters (MCTs) of the solute carrier 16 (SLC16) family. Malfunction, overexpression or absence of transporters...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosshart, Patrick D., Kalbermatter, David, Bonetti, Sara, Fotiadis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814091/
https://www.ncbi.nlm.nih.gov/pubmed/36697570
http://dx.doi.org/10.1038/s42004-021-00564-5
_version_ 1784864058898382848
author Bosshart, Patrick D.
Kalbermatter, David
Bonetti, Sara
Fotiadis, Dimitrios
author_facet Bosshart, Patrick D.
Kalbermatter, David
Bonetti, Sara
Fotiadis, Dimitrios
author_sort Bosshart, Patrick D.
collection PubMed
description L-lactate is an important metabolite, energy source, and signaling molecule in health and disease. In mammals, its transport across biological membranes is mediated by monocarboxylate transporters (MCTs) of the solute carrier 16 (SLC16) family. Malfunction, overexpression or absence of transporters of this family are associated with diseases such as cancer and type 2 diabetes. Moreover, lactate acts as a signaling molecule and virulence factor in certain bacterial infections. Here, we report the rational, structure-guided identification of potent, nanomolar affinity inhibitors acting on an L-lactate-specific SLC16 homologue from the bacterium Syntrophobacter fumaroxidans (SfMCT). High-resolution crystal structures of SfMCT with bound inhibitors uncovered their interaction mechanism on an atomic level and the role of water molecules in inhibitor binding. The presented systematic approach is a valuable procedure for the identification of L-lactate transport inhibitors. Furthermore, identified inhibitors represent potential tool compounds to interfere with monocarboxylate transport across biological membranes mediated by MCTs.
format Online
Article
Text
id pubmed-9814091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98140912023-01-10 The making of a potent L-lactate transport inhibitor Bosshart, Patrick D. Kalbermatter, David Bonetti, Sara Fotiadis, Dimitrios Commun Chem Article L-lactate is an important metabolite, energy source, and signaling molecule in health and disease. In mammals, its transport across biological membranes is mediated by monocarboxylate transporters (MCTs) of the solute carrier 16 (SLC16) family. Malfunction, overexpression or absence of transporters of this family are associated with diseases such as cancer and type 2 diabetes. Moreover, lactate acts as a signaling molecule and virulence factor in certain bacterial infections. Here, we report the rational, structure-guided identification of potent, nanomolar affinity inhibitors acting on an L-lactate-specific SLC16 homologue from the bacterium Syntrophobacter fumaroxidans (SfMCT). High-resolution crystal structures of SfMCT with bound inhibitors uncovered their interaction mechanism on an atomic level and the role of water molecules in inhibitor binding. The presented systematic approach is a valuable procedure for the identification of L-lactate transport inhibitors. Furthermore, identified inhibitors represent potential tool compounds to interfere with monocarboxylate transport across biological membranes mediated by MCTs. Nature Publishing Group UK 2021-09-06 /pmc/articles/PMC9814091/ /pubmed/36697570 http://dx.doi.org/10.1038/s42004-021-00564-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bosshart, Patrick D.
Kalbermatter, David
Bonetti, Sara
Fotiadis, Dimitrios
The making of a potent L-lactate transport inhibitor
title The making of a potent L-lactate transport inhibitor
title_full The making of a potent L-lactate transport inhibitor
title_fullStr The making of a potent L-lactate transport inhibitor
title_full_unstemmed The making of a potent L-lactate transport inhibitor
title_short The making of a potent L-lactate transport inhibitor
title_sort making of a potent l-lactate transport inhibitor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814091/
https://www.ncbi.nlm.nih.gov/pubmed/36697570
http://dx.doi.org/10.1038/s42004-021-00564-5
work_keys_str_mv AT bosshartpatrickd themakingofapotentllactatetransportinhibitor
AT kalbermatterdavid themakingofapotentllactatetransportinhibitor
AT bonettisara themakingofapotentllactatetransportinhibitor
AT fotiadisdimitrios themakingofapotentllactatetransportinhibitor
AT bosshartpatrickd makingofapotentllactatetransportinhibitor
AT kalbermatterdavid makingofapotentllactatetransportinhibitor
AT bonettisara makingofapotentllactatetransportinhibitor
AT fotiadisdimitrios makingofapotentllactatetransportinhibitor